Authors : Sagar Khokale; Dr. Laxmikant B Borse

Volume/Issue : Volume 9 - 2024, Issue 5 - May

Google Scholar : https://tinyurl.com/bdnpws9h

Scribd : https://tinyurl.com/3drpww3t

DOI : https://doi.org/10.38124/ijisrt/IJISRT24MAY1667

Abstract : In search for healthy, natural pain relief options is still underway, and salicin from willow bark is a historically significant molecule. The goal of this work is to create a salicin-enriched topical gel formulation as a cutting-edge method of treating pain and inflammation. The objective of this study is to create and assess a salicin- enriched gel made from willow bark, which may be used topically to treat pain and inflammation in place of oral or synthetic drugs. Willow bark was used to extract salicin, which was then added to a topical gel base. The permeability, salicin concentration, and physical stability of the formulation were evaluated.Efficacy was evaluated through in-vitro skin permeation studies and in-vivo anti- inflammatory and analgesic models. The developed salicin- enriched gel demonstrated good physical stability and consistent release of salicin. In-vitro permeation studies indicated effective skin absorption, while in-vivo tests revealed significant reduction in inflammation and pain indicators compared to controls. The gel was well-tolerated with no adverse effects observed. The salicin-enriched gel from willow bark represents a promising topical alternative for pain and inflammation management. Its efficacy and safety profile suggest potential for further development and clinical use. Future studies focusing on larger-scale clinical trials and formulation optimization are warranted to fully establish its therapeutic value.

Keywords : Salicin, Willow Bark, Topical Gel, Pain Management, Inflammation, Phytotherapy.

References :

1. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8. doi: 10.1016/s0049-3848(03)00379-7. PMID: 14592543.
2. Schmid B, Lüdtke R, Selbmann HK, Kötter I, Tschirdewahn B, Schaffner W, Heide L. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial. Phytother Res. 2001 Jun;15(4):344-50. doi: 10.1002/ptr.981. PMID: 11406860.
3. Shara M, Stohs SJ. Efficacy and Safety of White Willow Bark (Salix alba) Extracts. Phytother Res. 2015 Aug;29(8):1112-6. doi: 10.1002/ptr.5377. Epub 2015 May 22. PMID: 25997859.
4. Schmid B, Lüdtke R, Selbmann HK, Kötter I, Tschirdewahn B, Schaffner W, Heide L. Wirksamkeit und VerträglichkeiteinesstandardisiertenWeidenrindenextraktesbeiArthrose-Patienten: Randomisierte, Placebo-kontrollierteDoppelblindstudie [Effectiveness and tolerance of standardized willow bark extract in arthrosis patients. Randomized, placebo controlled double-blind study]. Z Rheumatol. 2000 Oct;59(5):314-20. German. doi: 10.1007/s003930070053. PMID: 11142926.
5. Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum. Pharmaceutics. 2015 Oct 22;7(4):438-70. doi: 10.3390/pharmaceutics7040438. PMID: 26506371; PMCID: PMC4695828.
6. Phillips HN, Sharpe KT, Endres MI, Heins BJ. Effects of oral white willow bark (Salix alba) and intravenous flunixin meglumine on prostaglandin E2 in healthy dairy calves. JDS Commun. 2021 Oct 22;3(1):49-54. doi: 10.3168/jdsc.2021-0138. PMID: 36340684; PMCID: PMC9623693.
7. van der Merwe J, Steenekamp J, Steyn D, Hamman J. The Role of Functional Excipients in Solid Oral Dosage Forms to Overcome Poor Drug Dissolution and Bioavailability. Pharmaceutics. 2020 Apr 25;12(5):393. doi: 10.3390/pharmaceutics12050393. PMID: 32344802; PMCID: PMC7284856.
8. Kumar A, P N, Kumar M, Jose A, Tomer V, Oz E, Proestos C, Zeng M, Elobeid T, K S, Oz F. Major Phytochemicals: Recent Advances in Health Benefits and Extraction Method. Molecules. 2023 Jan 16;28(2):887. doi: 10.3390/molecules28020887. PMID: 36677944; PMCID: PMC9862941.
9. Mourits, M. P. H., Koornneef, L., Wiersinga, W. M., Prummel, M. F., Berghout, A., & Van Der Gaag, R. (1989). Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. British Journal of Ophthalmology, 73(8), 639-644.
10. Sauer, R. S., Rittner, H. L., Roewer, N., Sohajda, T., Shityakov, S., Brack, A., &Broscheit, J. A. (2017). A novel approach for the control of inflammatory pain: prostaglandin E2 complexation by randomly methylated β-cyclodextrins. Anesthesia& Analgesia, 124(2), 675-685.
11. Leduc, C., Coonishish, J., Haddad, P., &Cuerrier, A. (2006). Plants used by the Cree Nation of EeyouIstchee (Quebec, Canada) for the treatment of diabetes: a novel approach in quantitative ethnobotany. Journal of Ethnopharmacology, 105(1-2), 55-63.
12. Suroowan, S., &Mahomoodally, F. (2018). Herbal products for common auto-inflammatory disorders-novel approaches. Combinatorial Chemistry & High Throughput Screening, 21(3), 161-174.
13. Brenner, M., Braun, C., Oster, M., &Gulko, P. S. (2006). Thermal signature analysis as a novel method for evaluating inflammatory arthritis activity. Annals of the rheumatic diseases, 65(3), 306-311.
14. Maffulli, N., Longo, U. G., &Denaro, V. (2010). Novel approaches for the management of tendinopathy. JBJS, 92(15), 2604-2613.
15. Marui, A., Tabata, Y., Kojima, S., Yamamoto, M., Tambara, K., Nishina, T., ...&Komeda, M. (2007). A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel an initial report of the Phase I-IIa Study. Circulation Journal, 71(8), 1181-1186.